NANS 2021: Nevro’s HF10 Spinal-Cord Stimulator Succeeds In Two Trials
Executive Summary
SENZA PDN showed Nevro's HF10 spinal cord stimulation therapy provided sustained relief to patients with painful diabetic neuropathy. Results of a separate trial showed HF10 improved outcomes in patients with non-surgical refractory back pain.
You may also be interested in...
Nevro Turns To Clinical Evidence To Attract Doctors, Patients And Reimbursement For Pain Therapy
The FDA recently approved Nevro’s Senza high-frequency spinal cord stimulation systems to treat pain caused by diabetic neuropathy. Now it plans to expand its proprietary HFX high-frequency treatment to more indications.
NANS 2021: Boston Scientific Advances New Personalized Pain Therapy
Boston Scientific’s WaveWriter Alpha spinal cord stimulation devices feature the proprietary FAST software for rapid, paresthesia-free pain relief of chronic pain.
NANS 2020: Boston Scientific Expects Neuromodulation Business Rebound In 2020
At NANS, Boston Scientific presented results of the COMBO study, announced a partnership with IBM Research on digital health, and reported strong US growth in its deep brain stimulation business. Boston's C suite sees rebound for lagging neuromodulation business in 2020.